By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Development of MasterKey therapies that target families of oncogenic mutations in patients with70M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States70M100.00%